Literature DB >> 11095338

Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice?

P M Boyce1, N A Koloski, N J Talley.   

Abstract

OBJECTIVES: It has been suggested that the variation in the prevalence of irritable bowel syndrome (IBS) may be due to the application of different diagnostic criteria. New criteria for IBS have been proposed (Rome II). It is unknown whether persons meeting different criteria for IBS have similar psychological and symptom features. The aim of this study was to measure the prevalence of IBS according to Manning and Rome definitions of IBS and to evaluate the clinical and psychological differences between diagnostic categories.
METHODS: A total of 4500 randomly selected subjects, with equal numbers of male and female subjects aged > or = 18 yr and representative of the Australian population, took part in this study. Subjects were mailed a questionnaire (response rate, 72%). Characteristics measured were gastrointestinal symptoms over the past 12 months, neuroticism and extroversion (Eysenck Personality Questionnaire), anxiety and depression (Delusions-Symptoms-States Inventory), mental and physical functioning (SF-12), and somatic distress (Sphere).
RESULTS: The prevalence for IBS according to Manning, Rome I, and Rome II was 13.6% (95% confidence interval [CI] = 3.5-5.1%), 4.4% (CI 6.0-7.8%), and 6.9% (CI 12.3-14.8%), respectively [corrected]. Only 12 persons with Rome I did not also meet Rome II criteria; 196 persons with Manning criteria did not meet Rome II cut-offs. Having IBS regardless of which criteria were used was significantly associated with psychological morbidity, but psychological factors were not important in discriminating between diagnostic categories. However, pain and bowel habit severity independently discriminated between diagnostic groups.
CONCLUSIONS: IBS is a relatively common disorder in the community. The new Rome II criteria may be unnecessarily restrictive in practice.

Entities:  

Mesh:

Year:  2000        PMID: 11095338     DOI: 10.1111/j.1572-0241.2000.03197.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  62 in total

1.  Potential psychosocial risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study.

Authors:  Roger B Fillingim; Richard Ohrbach; Joel D Greenspan; Charles Knott; Ronald Dubner; Eric Bair; Cristina Baraian; Gary D Slade; William Maixner
Journal:  J Pain       Date:  2011-11       Impact factor: 5.820

2.  Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study.

Authors:  Uday C Ghoshal; Philip Abraham; Shobna J Bhatia; Sri Prakash Misra; Gourdas Choudhuri; K D Biswas; Karmabir Chakravartty; Sunil Dadhich; B D Goswami; V Jayanthi; Sunil Kumar; Abraham Koshy; K R Vinay Kumar; Govind Makharia; Sandeep Nijhawan; Nitesh Pratap; Gautam Ray; Sanjeev Sachdeva; Shivaram Prasad Singh; Varghese Thomas; Harsh Udawat
Journal:  Indian J Gastroenterol       Date:  2013-09-03

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

4.  Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index.

Authors:  Masae Shinozaki; Motoyori Kanazawa; Yasuhiro Sagami; Yuka Endo; Michio Hongo; Douglas A Drossman; William E Whitehead; Shin Fukudo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

5.  A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients.

Authors:  Kyung Sik Park; Sung Hun Ahn; Jae Seok Hwang; Kwang Bum Cho; Woo Jin Chung; Byung Kuk Jang; Yu Na Kang; Jung Hyeok Kwon; Young Hwan Kim
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

6.  Medical treatment of irritable bowel syndrome.

Authors:  Jason Reina; James W Smith
Journal:  Clin Colon Rectal Surg       Date:  2005-05

7.  Modulation of sleep quality and autonomic functioning by symptoms of depression in women with irritable bowel syndrome.

Authors:  Jennifer J T Robert; William C Orr; Sigrid Elsenbruch
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

8.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

Review 9.  New developments in the diagnosis and treatment of irritable bowel syndrome.

Authors:  George F Longstreth; Douglas A Drossman
Journal:  Curr Gastroenterol Rep       Date:  2002-10

10.  Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.

Authors:  Xavier Badia; Fermin Mearin; Agustin Balboa; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Mentse Roset; Nicholas J Talley
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.